Skip to content

Study · Animal study (in vivo) · rat · 2012

3 results

Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration.

Szabadfi K, Danyadi B, Kiss P, Tamas A, Fabian E, Gabriel R, Reglodi D

Journal of molecular neuroscience : MN29 Apr 2012Cited by 17 (Europe PMC)

PMID22544514 (opens in a new tab)DOI10.1007/s12031-012-9774-9 (opens in a new tab)PepBankPUB-22544514
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischaemic retinal lesions, intravitreal VIP at 1,000 pmol had significant protective effects on retinal morphometry.

    In plain wordsIn rats with retinal injury, a higher VIP dose protected the retina's structure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseRetinal morphometry protection with VIP 1,000 pmol
    Study

    ratn: not reported in source

    BCCAO-induced ischaemic retinal lesion
    Comparator
    Untreated BCCAO retina
    Outcome group
    Neuroprotection · Eye
    Studied dose
    1,000 pmol · intravitreal injectionAs given in this study (rat).

    Source sentences

    Summary
    treatment with 1,000 pmol VIP, but not 100 pmol VIP, had significant protective effects in BCCAO-injured retina, as shown by the morphometric analysis.
    1 context sentence
    Summary · context
    Two-month-old rats were subjected to BCCAO and treated with intravitreal VIP injection.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischaemic retinal lesions, intravitreal VIP at 100 pmol had no significant protective effect on retinal morphometry.

    In plain wordsIn rats with retinal injury, a lower VIP dose did not protect the retina's structure.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeRetinal morphometry protection with VIP 100 pmol
    Study

    ratn: not reported in source

    BCCAO-induced ischaemic retinal lesion
    Comparator
    Untreated BCCAO retina
    Outcome group
    Neuroprotection · Eye
    Studied dose
    100 pmol · intravitreal injectionAs given in this study (rat).

    Source sentences

    Summary
    treatment with 1,000 pmol VIP, but not 100 pmol VIP, had significant protective effects in BCCAO-injured retina, as shown by the morphometric analysis.
    1 context sentence
    Summary · context
    Two-month-old rats were subjected to BCCAO and treated with intravitreal VIP injection.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with ischaemic retinal lesions, VIP was less effective than PACAP, which was already protective at 100 pmol.

    In plain wordsIn rats with retinal injury, VIP protected the retina less well than PACAP did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseNeuroprotection of VIP versus PACAP
    Study

    ratn: not reported in source

    BCCAO-induced ischaemic retinal lesion
    Comparator
    PACAP
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · intravitreal injectionAs given in this study (rat).

    Source sentences

    Summary
    Comparing the neuroprotective effects of VIP and PACAP in BCCAO-operated retinas, PACAP was more effective, already protective at 100-pmol doses.
    1 context sentence
    Summary · context
    Two-month-old rats were subjected to BCCAO and treated with intravitreal VIP injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:40 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.